A new treatment combining trastuzumab deruxtecan (T-DXd) and pertuzumab significantly reduces the risk of disease progression or death by 44% in patients with HER2-positive metastatic breast cancer a form affecting 15–20% of breast cancer cases.Presented at the American Society for Clinical Oncology meeting, the trial showed that patients on the new therapy had a median progression-free survival of 40.7 months, compared to 26.9 months with the current standard treatment (THP).T-DXd, already approved as a second-line therapy, may soon become the new first-line option pending regulatory approval. Experts hail it as a potential new standard for treating this aggressive cancer type.